Patent details

LUC00170 Product Name: Polatuzumab vedotin

Basic Information

Publication number:
LUC00170
Type:
SPC
SPC Type:
Medical
Basic Patent Number:
EP121531503
Legal Status:
Inactive
Application number:
LUC00170
First applicant's nationality:
Procedural language:
French

Marketing Authorization

Marketing Authorization Number:
EU/1/19/1388
Marketing Authorization Type:
Marketing Authorization Date:
20/01/2020
Marketing Authorization Status:
Accepted
Marketing Authorization Country:
Luxembourg (LU)

Dates

Filing date:
14/07/2020
First Marketing Authorization date:
20/01/2020
Grant date:
14/12/2021
Activation date:
Publication date:
15/07/2020
Lapsed date:
Expiration date:
Renunciation date:
Revocation date:
Annulment date:
Basic SPC Expiration:
15/07/2033
SPC Extension Expiration:
15/07/2033
Rejection date:
Withdrawal date:

Owner

From:
14/07/2020
 
 

Name:
Genentech Inc.
Address:
1 DNA Way, South San Francisco, CA 94080, United States (US)

Agent

Name:
OFFICE FREYLINGER S.A.
From:
14/07/2020
Address:
Boîte Postale 48, L-8001, STRASSEN, Luxembourg (LU)
To:

Publication

Bulletin

1

Bulletin Heading:
SPC1
Bulletin edition number:
2020/09
Publication date:
04/08/2020
Description:
Section C : Published requests for Supplementary Protection Certificates – I1 publication

2

Bulletin Heading:
SPC2
Bulletin edition number:
2022/01
Publication date:
03/01/2022
Description:
Section D : Granted supplementary protection certificates – I2 publication

Annual Fees

Annual Fee Due Date:
31/07/2028
Annual Fee Number:
21
Annual Fee Amount:
410 Euro
Expected Payer:
Last Annual Fee Payment Date:
Last Annual Fee Paid Number:
Payer:
Filing date Document type Number of pages
14/07/2020 General Document 3
15/07/2020 Outgoing Correspondence 1
14/07/2020 Application Form 4
14/07/2020 General Document 2
14/07/2020 General Document 42
14/07/2020 General Document 11
14/12/2021 Publication 1
14/12/2021 Certificate 1
14/12/2021 Outgoing Correspondence 1
15/07/2020 Publication 1